Cargando…
Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
Psoriasis (PsO) is a chronic, systemic, immune-mediated inflammatory skin disease affecting 1% to 5% population worldwide. In one-third of patients, the first symptoms of PsO manifest in childhood, with a mean age of nine years. Psoriasis in children under 16 years of age constitutes 4% of dermatolo...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940655/ https://www.ncbi.nlm.nih.gov/pubmed/36815128 http://dx.doi.org/10.2147/PPA.S350753 |